AUTHORS
Alexander Coltoff, MD, Shay Bellasea2, Megan Othus, PhD3, Uma Borate, MBBS, MSc4, Aaron T. Gerds, MD, MS5, Joseph M Unger, PhD, MS6, Xueyan Chen, MD, PhD7, Kathy Albain8, Anjali Sunder Advani, MD9, Harry Erba, MD, PhD10
AFFILIATIONS
1 Medical University of South Carolina, Charleston, United States
2 Fred Hutchinson Cancer Center, Seattle, United States
3 Fred Hutchinson Cancer Center, Seattle, United States
4 The Ohio State University Comprehensive Cancer Center, Columbus, United States
5 Cleveland Clinic Taussig Cancer Institute, Cleveland, United States
6 Fred Hutchinson Cancer Center, Seattle, United States
7 Fred Hutchinson Cancer Center, Seattle, United States
8 Loyola University Chicago Stritch School of Medicine, Maywood, United States
9 Cleveland Clinic Taussig Cancer Institute, Cleveland, United States
10 Duke Cancer Institute, Durham, United States
ABSTRACT
Introduction and Rationale:
Myelofibrosis (MF) is a Philadelphia-chromosome negative myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and a risk of transformation to acute leukemia. The JAK inhibitor (JAKi) ruxolitinib can improve the symptoms of MF and decrease splenomegaly, but is myelosuppressive and leads to new or worsened anemia and thrombocytopenia in a population that often has baseline cytopenias. It is estimated that 70-75% of patients with MF have some degree of cytopenia at diagnosis and that an additional 10-15% will develop cytopenia(s) by the time they initiate treatment (Masarova et al, ASCO 2025). Cytopenias can limit adequate dosing of ruxolitinib, which can predispose to suboptimal spleen and symptom responses (Palandri et al, Cancer 2023).
Momelotinib is a minimally myelosuppressive JAKi that may be associated with superior outcomes in cytopenic MF, as it obviates the need for cytopenia-related dose reductions. A post-hoc analysis of the SIMPLIFY-1 study, which randomized JAKi-naive MF patients to treatment with momelotinib vs ruxolitinib, demonstrated improved spleen response (SVR35) rates for momelotinib in bicytopenic MF, specifically in patients with hemoglobin < 10 g/dL and platelets < 200 x 103/uL (Palandri et al EHA 2025). The same analysis demonstrated an improvement in combined SVR35 + red blood cell transfusion independence with momelotinib vs ruxolitinib.
Ruxolitinib is still used frequently in cytopenic MF despite data suggesting decreased efficacy with compromised dosing strategies. A phase 3b, expanded-access study of ruxolitinib showed that spleen responses were lower in patients with platelets < 100 x 103/uL, likely from cytopenia-driven dose decreases (Al-Ali et al, BJH 2020). Similar findings of compromised efficacy in cytopenic patients were noted in the retrospective RUX-MF study (Palandri et al, Cancer 2023).
We hope to provide insight on the optimal first-line treatment of cytopenic MF by conducting a prospective, randomized study of momelotinib vs dose-adjusted ruxolitinib in patients with baseline anemia and thrombocytopenia. We hypothesize that momelotinib will be superior to ruxolitinib in cytopenic MF with regards to a combined rate of spleen and transfusion response given the aforementioned retrospective analysis in this patient population from SIMPLIFY-1.
Study Design and Methods:
APEX-MF (NCT07498205; 26CTP.LEUK02) is a randomized, open-label trial comparing momelotinib and dose-adjusted ruxolitinib (for anemia and/or thrombocytopenia) in patients with cytopenic MF. Patients will be randomized 2:1 to momelotinib or dose-adjusted ruxolitinib. The study will be conducted through SWOG under the SWOG Clinical Trials Partnerships (CTP) Program. Eligible patients must be JAKi-naive, have splenomegaly ≥450 cm3, DIPSS intermediate-1 risk or higher, hemoglobin < 10 g/dL and platelets 50-200 x 103/uL. Other relevant inclusion criteria include age ≥18 years, ECOG ≤2 and <10% blasts in the blood and bone marrow. The study attempts to reflect real-world MF management by not restricting the use of anemia-directed therapies (e.g., luspatercept, erythropoiesis-stimulating agents) and by allowing physician discretion regarding ruxolitinib dose adjustments for cytopenias.
The primary endpoint will be dual response: both spleen response (SVR35) + red blood cell transfusion independence at week 24 post-randomization. Participants will be allowed to crossover to the alternative JAKi after week 24. Total accrual is anticipated to be 268 patients. The trial will be conducted as a multicenter study within the United States.
Secondary endpoints include SVR35 alone, red blood cell transfusion independence alone, major anemia response per 2024 IWG-ELN criteria, time to initiation of anemia-directed therapy, progression-free survival and overall survival. QOL objectives include evaluation of disease- and anemia-related symptoms using the MF-SAF v4.0 and FACT-An, respectively. Specimens will be banked for exploratory correlative studies to be informed by the overall study results. The trial is expected to begin accrual during the latter part of 2026.
Funding/product for this study was provided by GlaxoSmithKline, LLC [NCT07498205]. GlaxoSmithKline, LLC, was provided the opportunity to provide a courtesy review of the preliminary version of this publication for accuracy only, but the authors are solely responsible for final content and interpretation.
DISCLOSURES
Alexander Coltoff, MD: Blueprint Medicines - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony)